BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20036027)

  • 1. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
    Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
    de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
    Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.
    Gridelli C; de Marinis F; Di Maio M; Ardizzoni A; Belani CP; Cappuzzo F; Ciardiello F; Fidias P; Paz-Ares L; Perrone F; Pirker R; De Petris L; Stahel R
    Lung Cancer; 2012 Jun; 76(3):269-79. PubMed ID: 22266040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
    Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
    J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT).
    Gridelli C; Rossi A; de Marinis F
    Lung Cancer; 2010 Mar; 67(3):339-42. PubMed ID: 19481831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing first-line treatment options for patients with advanced NSCLC.
    Wakelee H; Belani CP
    Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Balducci L; Ciardiello F; Di Maio M; Felip E; Langer C; Lilenbaum RC; Perrone F; Senan S; de Marinis F
    Clin Lung Cancer; 2015 Sep; 16(5):325-33. PubMed ID: 25862554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
    Yoshida T; Zhang G; Haura EB
    Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending survival of stage IV non-small cell lung cancer.
    Carnio S; Novello S; Mele T; Levra MG; Scagliotti GV
    Semin Oncol; 2014 Feb; 41(1):69-92. PubMed ID: 24565582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine for lung cancer: new challenges for pathology.
    Kerr KM
    Histopathology; 2012 Mar; 60(4):531-46. PubMed ID: 21916947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of histology in the management of advanced non-small-cell lung cancer.
    Langer CJ; Besse B; Gualberto A; Brambilla E; Soria JC
    J Clin Oncol; 2010 Dec; 28(36):5311-20. PubMed ID: 21079145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized therapy of lung cancer.
    Thomas R; Wolf J
    Onkologie; 2012; 35 Suppl 1():14-9. PubMed ID: 22286583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.